BIO vs CCEL · rev $2.58B vs P/E 490, $39.6M cap
BIO (BIO) versus CryoCell International Inc (CCEL) — a side-by-side from cached financials, not a winner call.
BIO (BIO) common stock.
CryoCell International Inc (CCEL) is a medical care facilities company listed on US.
Latest reported BIO revenue for 2025-12-31 was $2.58B. Net income was $759.9M. Revenue was up 0.7% from 2024-12-31 to 2025-12-31. BIO currently screens at market cap $0.
CCEL does not have a complete income-statement cache yet.
BIO currently screens at market cap $0. CCEL currently screens at market cap $39.6M and trailing P/E 490.0.
Not investment advice. Open the BIO and CCEL stock pages for the full models.
Not investment advice.